Actos Side Effects Not Worth The Risk, Says Consumer Reports
Actos side effects are so severe that Consumer Reports has dubbed the type 2 diabetes drug a “last resort,” Bernstein Liebhard LLP reports.
New York, NY (PRWEB) September 07, 2012
Actos side effects are so serious that Consumer Reports is advising the public that the newly approved generic version of the type 2 diabetes drug is “one ℠bargain´ to avoid,” Bernstein Liebhard LLP reports.* Amidst mounting lawsuits and studies linking the popular diabetes drug to bladder cancer, on August 17, 2012, the U.S. Food and Drug Administration (“FDA”) approved the first generic version of Actos.** The generic version, pioglitazone, manufactured by Mylan Pharmaceuticals, gained FDA approval for 15 milligram, 30 mg and 45 mg tablets. Prompted by the FDA´s action, the consumer advocacy group went on the attack, and issued a public health announcement warning diabetics of Actos side effects, which include an increased risk of heart failure, bone fractures, and bladder cancer. Diabetics should instead consider metformin, either alone or with glipizide or glimepiride. According to the medical advisers at Consumer Reports, “people with diabetes should use pioglitazone, generic or brand-name Actos, only as a last resort.”
“Given the findings of various studies and warnings about the dangers associated with Actos, we applaud Consumer Reports for issuing this public health alert,” said Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs and defective medical devices. The Firm is currently offering free and confidential case reviews to individuals who took Actos and have been diagnosed with bladder cancer.
Bladder Cancer Subject Of Actos Lawsuits
Despite the FDA´s decision to approve the first generic version of the medication, Actos lawsuits continue to move forward. On July 13, 2012, the Honorable Rebecca Doherty, who is overseeing the federal consolidated action, In re: Actos (Pioglitazone) Products Liability Litigation (“MDL No. 2299”), currently underway in the U.S. District Court for the Western District of Louisiana, issued an order setting out deadlines for the course of the Actos litigation.*** According to the order, the first federal Actos bladder cancer lawsuit trial is scheduled to begin on November 3, 2014 with the second trial set for July 8, 2015. Plaintiffs involved in the Actos litigation allege that the drug caused them to develop bladder cancer and that the manufacturer failed to warn consumers about the risks associated with Actos use.
Those who developed bladder cancer as a result of taking Actos may be able to collect compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about the Actos litigation by visiting our website, http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html. For more information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9880176.htm